MOR News and Press, MorphoSys AG From 07/01/21

MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / July 1, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), for its tender offer for Constellation P...

Zhanna Hapanovich/iStock via Getty Images Constellation Pharmaceuticals (CNST) said the waiting period under the HSR act expired for its planned $1.7B sale to MorphoSys (MOR) expired yesterday. Conditions on the offer have been satisfied, according to an 8-K filing. Last month, MorphoSys...

Alex Potemkin/iStock Unreleased via Getty Images Sensei downgraded, price trimmed on program discontinuation Oppenheimer has downgraded shares of Sensei Biotherapeutics (SNSE) from outperform to perform and has removed its $36 price target in the wake of discontinuing the SNS-301 program for&...

If approved, tafasitamab in combination with lenalidomide would represent an important new therapeutic option for eligible DLBCL patients in the European Union The positive opinion from the CHMP is based on data from the Phase 2 L-MIND study evaluating tafasitamab in combination with l...

- If approved, tafasitamab in combination with lenalidomide would represent an important new therapeutic option for eligible DLBCL patients in the European Union - The positive opinion from the CHMP is based on data from the Phase 2 L-MIND study evaluating tafasitamab in combi...

Christian Kaspar-Bartke/Getty Images News BofA downgrades CureVac following disappointing COVID vaccine data Following the release yesterday of disappointing data in a phase 2b/3 trial of its COVID-19 vaccine, BofA Securities has downgraded shares of CureVac (CVAC) from buy to neutral and cut...

PLANEGG, GERMANY / ACCESSWIRE / June 16, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) ("MorphoSys") today announced that it is commencing a cash tender offer to purchase all outstanding shares of Constellation Pharmaceuticals, Inc., (CNST) ("Constellation") for $34.00 per share, net to the sel...

Regional bank consolidation continues with three new bank deals announced last week. Extended Stay America catches a higher bid. Chamath Palihapitiya files for four new biotech-focused SPACs. For further details see: Merger Arbitrage Mondays: Extended Stay America Receiv...

According to new three-year follow-up data disclosed by Incyte ([[INCY]] +0.6%) and MorphoSys US ([[MOR]] +6.2%), tafasitamab (Monjuvi) and lenalidomide combination has improved patient outcomes in a Phase 2 trial for relapsed or refractory diffuse large B-cell lymphoma ((DLBCL)).The single a...

Presentation will be available on demand as part of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting BOSTON, MA and WILMINGTON, DE / ACCESSWIRE / June 4, 2021 / MorphoSys US Inc., a fully owned subsidiary of MorphoSys AG (FSE:MOR) (NASDAQ:MOR), and Incyte (NASDAQ:I...